The very low-density lipoprotein receptor (VLDLR) is a cell-surface protein belonging to the low-density lipoprotein receptor (LDLR) family, primarily involved in lipid metabolism and cellular signaling. It binds apolipoprotein E (apoE)-containing lipoproteins, facilitating their uptake into cells via endocytosis. VLDLR is widely expressed in tissues such as the brain, heart, and skeletal muscle, playing roles in neuronal migration, angiogenesis, and energy homeostasis. Dysregulation of VLDLR has been linked to metabolic disorders, atherosclerosis, and neurological conditions like cerebellar hypoplasia.
VLDLR antibodies are immunological tools targeting specific epitopes of the receptor, used to study its expression, localization, and function. These antibodies are critical in research applications, including Western blotting, immunohistochemistry, and flow cytometry, enabling the investigation of VLDLR's role in lipid transport, receptor-mediated endocytosis, and disease mechanisms. Monoclonal antibodies offer high specificity, while polyclonal antibodies detect multiple epitopes, enhancing sensitivity. Recent studies also explore therapeutic potentials, such as modulating VLDLR activity to treat metabolic or neurodegenerative diseases. Validation of VLDLR antibodies requires rigorous testing to ensure minimal cross-reactivity with related LDLR family members, ensuring reliability in experimental and diagnostic contexts.